# A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

> **NCT03234712** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 62 (actual)

## Conditions studied

- Advanced Solid Tumors Cancer

## Interventions

- **DRUG:** ABBV-321

## Key facts

- **NCT ID:** NCT03234712
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-10
- **Primary completion:** 2021-04-14
- **Final completion:** 2021-04-14
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234712, "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03234712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*